Founded in April 2001, Zein Biotechnology has research and development bases, production bases for raw materials and formulations, and sales companies in various regions. It is a national high-tech enterprise that integrates pharmaceutical research and development, manufacturing, sales, and health services. The company focuses on building a drug lifecycle management service system, providing drug lifecycle services such as research and development, manufacturing, transaction promotion, and post market research through a combination of product (service) delivery and commodity trading services, with MAH (drug marketing license holder) as the core.
The company adheres to innovative development as the driving force and builds core research and development capabilities. The R&D team has over 20 core experts with over ten years of R&D management experience in domestic and foreign pharmaceutical companies, with over 80% of them having a bachelor's degree or above. Our research products cover different fields such as pharmaceuticals, biopharmaceuticals, and traditional Chinese medicine, with over 50 ongoing projects. We possess key technologies in asymmetric catalytic total synthesis, synthetic biology (enzyme catalysis technology), sustained-release formulation technology, liposome formulation technology, and more. We have accumulated 46 production approvals, 117 domestic and foreign patents, and 666 authorized trademarks. Obtained national level qualifications such as National Enterprise Technology Center, National Specialized and Innovative "Little Giant" Enterprise, National Intellectual Property Demonstration Enterprise, and National Local Joint Engineering Research Center for Advanced Pharmaceutical Manufacturing Technology; Received multiple municipal honors, including Chongqing Postdoctoral Research Workstation, Chongqing New Drug Design Engineering Technology Research Center, Chongqing Chiral Drug Engineering Technology Research Center, and Innovative Drugs and Advanced Drug Manufacturing Technology Engineering Research Center. We have 4 domestic first varieties, 1 domestic exclusive variety, and 6 varieties that have passed consistency evalsuation (including 3 varieties that have passed national consistency evalsuation).
The company's key products that have been listed include Olistat capsules (for weight loss), Donepezil hydrochloride tablets (for Alzheimer's disease), Ropinolo hydrochloride tablets (for Parkinson's disease), Quetiapine fumarate sustained-release tablets (for antipsychotic drugs), and Tropisetron hydrochloride injection (for chemotherapy and radiation therapy). Among them, the company's flagship product Olistat adopts the world's first asymmetric catalytic total synthesis technology, and its core patented technology has won the second prize of the National Technology Invention Award. It is the first product in China to pass the national drug quality and efficacy consistency evalsuation. The company is currently the world's largest supplier of Orlistat raw materials and formulations, with the world's first industrial production of fully synthetic raw materials and the first domestic production base to achieve localization. Around the pharmaceutical industry service chain, the company has invested in the construction of multiple research and development and manufacturing bases for chemical raw materials, chemical preparations, biopharmaceuticals, traditional Chinese medicine, vaccines, etc., possessing advanced transformation and manufacturing capabilities in the fields of chemical medicine, traditional Chinese medicine, biopharmaceuticals, etc.
In combination with "Internet plus", the company has continuously integrated medical, medical and user data information, built a smart pharmaceutical trading service system, built a full scene and efficient operation service capability with AI technology as the core, and enabled the trading channel market. We have exported raw materials to over 40 countries and regions, with over 200000 B2B businesses and over 22 million C-end service users. We ship over 7.58 million packages annually (covering all provinces and autonomous regions in China) and provide medication guidance for over 2 million people.
The company has established project cooperation with well-known domestic and foreign biopharmaceutical enterprises such as Cytiva, Shanghai Junshi Biosesciences Co., Ltd. , and Dragon Sail Pharmaceutical Co., Ltd. to support the development of Chongqing's biopharmaceutical industry cluster. Among them, we signed a strategic cooperation agreement with Cytiva, a subsidiary of Danaher, to jointly build the Situofan Western Science and Technology Innovation Center, and rely on the platform to carry out business expansion work such as project incubation, BD, and investment; The two sides signed a cooperation agreement with Junshi Biosesciences. The two sides will take the MAH company Chongqing Bochuang Medicine, the first blood lipid management field in the MAH cluster, as the main body of MAH to carry out commercial cooperation on the targeted PCSK9 monoclonal antibody "Angorisimab" in Chinese Mainland, and create a standardized system for the commercial cooperation of multiple varieties of biological drugs; Introduce Mabwell (Shanghai) Biotechnology Co., Ltd. to participate in Feifan (Chongqing) Biopharmaceutical Co., Ltd., jointly build the Western Science City Biopharmaceutical CDMO Advanced Manufacturing Base, and achieve localized production of multiple varieties of biopharmaceuticals; We have signed a cooperation agreement with the Management Committee of Chongqing High tech Industrial Development Zone, Mabwell (Shanghai) Biotechnology Co., Ltd. (688062. SH), and Chongqing Zhongxin Pharmaceutical Big Health Private Equity Investment Fund Partnership Enterprise to jointly build the Western Science City Biopharmaceutical MAH Cluster, achieve product clustering, drive supply chain entry into Chongqing, and work together to promote the leapfrog development of biopharmaceuticals in Chongqing.
Wood grows straight from the heart, and medicine grows from the heart. Zein Biotechnology will always be committed to building a pharmaceutical full lifecycle management service ecosystem, with MAH as the core, continuously providing more professional, efficient, and reliable pharmaceutical full lifecycle services, creating better drugs, meeting the public's pursuit of life and health, and striving to become a leading pharmaceutical and health service enterprise in the world.
